Seer Inc., a biotechnology company based in Redwood City, United States, operates within the Health Care sector and is listed on the Nasdaq stock exchange. The company specializes in offering proprietary engineered nanoparticles combined with an automated assay solution. This innovative combination provides an unmatched workflow that is unbiased, deep, rapid, and scalable, enabling a clearer view of the proteome. Seer Inc. primarily serves customers within the United States and can be accessed online at www.seer.bio .
As of February 3, 2026, Seer Inc.’s stock closed at $1.81, marking a modest increase of 1.1% from its last trading day on January 6, 2026. Over the past year, the stock has experienced limited volatility, with its price fluctuating between a low of $1.62 on April 3, 2025, and a high of $2.41 on October 23, 2025. This range indicates a relatively stable performance in the market.
Despite the stability in its stock price, Seer Inc. faces challenges reflected in its financial metrics. The company’s price-to-earnings (P/E) ratio stands at -1.32, indicating a loss-generating status. This negative P/E ratio suggests that the company is not currently profitable. Additionally, the price-to-book (P/B) ratio of 0.377 implies that the market values Seer Inc.’s stock below its book value, further highlighting the financial hurdles the company faces.
With a market capitalization of $100,690,000 USD, Seer Inc. continues to navigate the competitive landscape of the biotechnology sector. As of the latest reports, no new developments have emerged since January 6, 2026, and the company’s valuation metrics remain unchanged. Investors and stakeholders are likely to monitor Seer Inc. closely for any strategic moves or innovations that could potentially enhance its financial performance and market position.
